Oncogenic EME1 promotes tumor progression and immune modulation in human cancers with therapeutic targeting potential
This study reveals the multifaceted oncogenic roles of EME1 in tumor progression, immune evasion, and prognosis. It proposes EME1 as a promising biomarker and therapeutic target across multiple cancer types. The identified drug candidates warrant further in vitro and in vivo validation for potential repurposing in EME1-targeted cancer therapy.
Authors
- Mohamed A. Soltan (ORCID: https://orcid.org/0000-0003-3030-1659)
- Farag Mamdouh
- Eman Elsayed Fayad (ORCID: https://orcid.org/0000-0003-2916-0254)
- Dalal Sulaiman Alshaya (ORCID: https://orcid.org/0000-0002-0682-8189)
- Muhammad Alaa Eldeen (ORCID: https://orcid.org/0000-0001-5280-7736)
- Mohammed Ali Alshehri (ORCID: https://orcid.org/0000-0002-0188-1634)
- Mostafa Abdelrahman (ORCID: https://orcid.org/0000-0002-6733-8423)
- Ghadi Alsharif (ORCID: https://orcid.org/0000-0002-0424-135X)
- Hassan M. Otifi (ORCID: https://orcid.org/0000-0002-1735-6041)
- Aiysha Althobaiti
- Hesham M. Hassan (ORCID: https://orcid.org/0000-0002-8029-914X)
- Walid K Abdulsahib
Institutions
- Princess Nourah bint Abdulrahman University (SA)
- Sinai University (EG)
- Taif University (SA)
- King Saud bin Abdulaziz University for Health Sciences (SA)
- Zagazig University (EG)
- Benha University (EG)
- King Saud Medical City (SA)
- King Saud University (SA)
- Iraqi University (IQ)
- King Abdullah International Medical Research Center (SA)
- King Khalid University (SA)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-10-13
- DOI
- https://doi.org/10.1007/s12672-025-03631-8
- Citations
- 1
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Princess Nourah Bint Abdulrahman University
- King Khalid University